Nano cap Can-Fite BioPharma (NYSEMKT:CANF) is up 16% premarket on average volume on the heels of its announcement that
it has “garnered interest” from prospective partners to develop
anti-rheumatic med Piclidenoson for the potential treatment of
coronavirus infection.
The company says the drug has shown antiviral effects against single-stranded RNA viruses (like SARS-CoV-2).
https://seekingalpha.com/news/3552875-can-fite-seeks-partner-to-develop-piclidenoson-for-coronavirus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.